- Healthcare Trust of America stock price today and history
Healthcare Trust of America (HTA) stock prices updated...
Please, Signup (Login) to subscribe or trade (demo)
Healthcare Trust of America stock price
Healthcare Trust of America latest news:
BRIEF-ACCC Institutes Proceedings Against GSK, Novartis
Australian Competition and Consumer Commission. * INSTITUTED PROCEEDINGS AGAINST GLAXOSMITHKLINE HEALTHCARE AUSTRALIA PTY LTD AND NOVARTIS CONSUMER HEALTH AUSTRALASIA. * PROCEEDINGS ALLEGING THEY MADE FALSE OR MISLEADING REPRESENTATIONS IN MARKETING OF VOLTAREN OSTEO GEL AND VOLTAREN EMULGEL PAIN RELIEF PRODUCTS.
Nestle to buy vitamin maker Atrium Innovations for $2.3 bln
Nestle is paying $2.3 billion to buy Canadian vitamin maker Atrium Innovations, it said on Tuesday, expanding its presence in the consumer healthcare market as it seeks to offset weakness in its traditional packaged foods. The world's largest packaged food company is buying Atrium, which is expected to have 2017 sales of $700 million, from a group of investors led by Permira Funds.
Nestle to buy vitamin maker Atrium Innovations for $2.3 billion
Nestle is paying $2.3 billion to buy Canadian vitamin maker Atrium Innovations, it said on Tuesday, expanding its presence in the consumer healthcare market as it seeks to offset weakness in its traditional packaged foods. The world's largest packaged food company is buying Atrium from a group of investors led by private equity firm Permira.
Google's Hinton says AI poses new challenges to regulators
Expansion of artificial intelligence in financial services, healthcare, transportation and other fields poses new challenges to governments charged with regulating those industries, according to an executive with Google who is a pioneer in the field of machine learning.
CVS, Aetna executives defend $69 billion deal to skeptical Wall Street
NEW YORK (Reuters) - CVS Health Corp and Aetna Inc on Monday said their $69 billion deal to combine the pharmacy and drug benefit manager and the No. 3 U.S. health insurer would transform healthcare and deliver cost savings, but investors took a pessimistic view of the combination in the short term.
UPDATE 3-CVS, Aetna executives defend $69 bln deal to skeptical Wall St
NEW YORK, Dec 4 (Reuters) - CVS Health Corp and
Aetna Inc on Monday said their $69 billion deal to
combine the pharmacy and drug benefit manager and the No. 3 U.S.
health insurer would transform healthcare and deliver cost
savings, but investors took a pessimistic view of the
combination in the short term.
GSK starts big African study of injectable drug to prevent HIV
ViiV Healthcare, GlaxoSmithKline Plc's HIV unit, said on Thursday it started an African study to evaluate long-acting injectable drug for the prevention of HIV infection in sexually active women. The cabotegravir study seeks to enrol 3,200 women aged 18 to 45 years from sub-Saharan African countries, ViiV Healthcare said in a statement.
BRIEF-Glaxosmithkline says ViiV Healthcare starts Phase 3 HIV prevention study in women
GLAXOSMITHKLINE PLC(GSK): * VIIV STARTS PHASE 3 HIV PREVENTION STUDY IN WOMEN. * VIIV HEALTHCARE, CO OWNED BY GSK, WITH PFIZER INC. AND SHIONOGI LTD AS SHAREHOLDERS, TO START PHASE III STUDY FOR PREVENTION OF HIV INFECTION IN SEXUALLY ACTIVE WOMEN Source text for Eikon: Further company coverage:
U.S. healthcare shares climb as investors see upside from Republican tax bill
Shares of U.S. healthcare companies mostly climbed on Wednesday, as investors saw some potential upside for the stocks from a Republican-led bill to cut taxes. Hospitals were among the biggest gainers on the day, with Community Health Systems (CYH) up 6.2 percent and shares of Tenet Healthcare (THC) up 5.2 percent.
BRIEF-Healthcare Realty Trust Expects To Record A Charge In Q4 Of Nearly $32.7 Mln For Early Extinguishment Of Notes
* HEALTHCARE REALTY TRUST ANNOUNCES REDEMPTION OF REMAINING
MILLION OF SENIOR NOTES DUE 2021
Nvidia, GE Healthcare announce deal to bring AI platform to hospitals
Nvidia Corp. and GE Healthcare, a subsidiary of General Electric Co. , announced a deal Sunday that will extend the companies' 10-year partnership and use Nvidia's sophisticated artificial-intelligence chips to speed up processing of health-care data. That includes the new Nvidia-powered Revolution Frontier CT system, which will process images two times faster for GE's 500,000 imaging devices worldwide. Nvidia's chips will also help speed the processing of the 50 petabytes of data that the average hospital produces annually. "Our partnership with GE Healthcare brings together great expertise in medical instruments and AI to create a new generation of intelligent instruments that can dramatically improve patient care," Nvidia CEO Jensen Huang said in a statement. GE Healthcare CEO Kieran Murphy concurred: "By partnering with Nvidia, GE Healthcare will be able to deliver devices of the future -- intelligent machines capable of empowering providers to improve the speed and accuracy of diagnoses for patients around the world."Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Fresenius says Akorn deal closure could take until next year
FRANKFURT, Nov 22 (Reuters) - German healthcare group
Fresenius SE said the planned takeover of Akorn
, a U.S. maker of liquid generic drugs, might not be
completed before next year as the U.S. antitrust review could
take longer than expected.
ViiV Healthcare says FDA has approved its two-drug HIV regimen, in first such instance
ViiV Healthcare, which is majority-owned by GlaxoSmithKline and has Pfizer Inc. and Shionogi as shareholders, said on Tuesday that the Food and Drug Administration has approved its two-drug HIV regimen. The therapy, Juluca, is the first such HIV drug composed of just two drugs -- dolutegravir and rilpivirine, both of which have been previously approved -- while other HIV regimens are typically composed of at least three drugs. This advancement could make the regimen more tolerable for the patient, according to Dr. Debra Birnkrant, director of the Division of Antiviral Products in the FDA's Center for Drug Evaluation and Research. Juluca is approved for individuals with HIV-1 who have been stable on a regimen for at least half a year, have no history of treatment failure and no known resistance to Juluca's individual components, ViiV said. GlaxoSmithKline shares declined 0.8% in Tuesday trade; shares have dropped nearly 10% over the last three months, compared with a 7% rise in the S&P 500 and a nearly 8% rise in the Dow Jones Industrial Average .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
GE to shrink, investors worry it will be less profitable
(Reuters) - General Electric Co will radically shrink to focus on aviation, power and healthcare, betting on sectors where it thinks it can make a profit, as the most famous U.S. conglomerate tries to end a decade and a half of share price stagnation.
Genesis Healthcare sees nursing home lease deals saving cash
CHICAGO, Nov 9 (Reuters) - Genesis Healthcare Inc,
one of the largest U.S. nursing home operators, expects to
bounce back from industry woes after reaching a deal to
restructure some of its leases, Chief Executive George Hager
told investors on Thursday.
BRIEF-Tenet Healthcare says Board now consists of 12 directors
Tenet Healthcare Corp(THC). * Tenet Healthcare(THC) says after appointment of two new independent directors, co's Board now consists of 12 directors - SEC filing Source text: Further company coverage:
BRIEF-Tenet healthcare Board approved raise in salary of CEO Ronald Rittenmeyer
* Tenet Healthcare- Human Resources Committee of Board
raise in salary of Ronald Rittenmeyer in recognition of his
assumption of co's CEO role
BRIEF-Northwest Healthcare Properties REIT announces intention to redeem two series of convertible debentures
* Northwest Healthcare Properties REIT announces intention
redeem two series of convertible debentures totalling $40
million with a weighted average interest rate of 7.0%
Source text for Eikon:
Further company coverage:
BRIEF-Tenet Board appoints two independent directors
Tenet Healthcare Corp(THC). * Tenet Board appoints two independent directors. * Tenet Healthcare Corp(THC) - Board now consists of 12 directors, 11 of whom are independent and 5 of whom have joined Board since November 2016 Source text for Eikon: Further company coverage:
UPDATE 4-Humana outlines 2018 growth challenges, shares fall
NEW YORK, Nov 8 (Reuters) - Health insurer Humana Inc
on Wednesday said its 2018 profit growth would be "a bit
below" 11 percent as the specialist in Medicare healthcare for
the elderly and disabled faces off against challenges such as
the reinstatement of a 3 percent industry-wide health insurance
BRIEF-ENSIGN GROUP ACQUIRES HOME HEALTH AND HOSPICE OPERATIONS IN OKLAHOMA CITY
Ensign Group Inc(ENSG): * THE ENSIGN GROUP ACQUIRES HOME HEALTH AND HOSPICE OPERATIONS IN OKLAHOMA CITY, OKLAHOMA. * ENSIGN - UNIT OF CORNERSTONE HEALTHCARE ACQUIRED ASSETS OF EXCELL HOME CARE AND HOSPICE, EXCELL PRIVATE CARE SERVICES IN OKLAHOMA CITY EFFECTIVE NOV 1 Source text for Eikon: Further company coverage:
U.S. investors target 'buyback stocks' in bet on Trump tax plan
Rather than waiting to see how the Republican tax bill will fare in Congress, some investors are already picking out gingerly technology, healthcare and consumer companies they expect to use potential tax savings to buy back more of their own stock.
BRIEF-Sensus Healthcare files for mixed shelf of up to $20 mln - SEC filing
* Sensus Healthcare Inc files for mixed shelf of up to $20
- SEC filing
Source text: (http://bit.ly/2j7hKwL)
Further company coverage:
Tenet shares fall after third-quarter results
Tenet Healthcare Corp. shares fell in the extended session Monday after the health care company announced its third-quarter earnings. Tenet shares fell 7% to $11.76 after hours, a 52-week low. The company reported a third-quarter net loss of $367 million, or $3.64 a share, compared with a loss of $8 million, or eight cents a share, in the year-ago period. Adjusted losses were 17 cents a share. Revenue rose to $4.94 billion from $4.85 billion in the year-ago period. Analysts surveyed by FactSet had estimated an adjusted loss of 34 cents a share on revenue of $4.63 billion. For the fourth quarter, analysts estimate adjusted earnings of $1.55 a share on revenue of $4.95 billion. Executives issued fourth-quarter guidance of adjusted earnings of $1.20 to $1.35 a share on revenue of between $4.8 billion and $5 billion. Tenet stock has dropped 14.8% this year, with the S&P 500 index rising 15.6%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
BRIEF-Sensus Healthcare reports Q3 loss per share of $0.07
* Sensus Healthcare reports third quarter financial results
featuring revenue up 44 percent
Pfizer sets date for auction of consumer healthcare unit: Reuters
Pfizer Inc. will begin the auction process for its consumer healthcare unit in November, which it hopes will end in a $15 billion sale, Reuters reported late Wednesday, citing sources close to the matter. GlaxoSmithKline PLC. and Reckitt Benckiser are among those companies that have said they would consider bidding for the Pfizer unit. One of the sources told Reuters that initial discussions with Reckitt have already happened. Other possible bidders may include Procter & Gamble , Sanofi SA , Johnson & Johnson and Nestle [s:
ch:nesn], sources said. The companies have been contacted for comment.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Exclusive: Pfizer to launch consumer health sale in November - sources
Pfizer plans to kick off an auction process for its consumer healthcare business in November, paving the way for a potential $15 billion-plus sale of the headache pill to lip balm business, sources close to the matter told Reuters.
Acadia Heathcare shares plunge on earnings, revenue miss
Shares of Acadia Healthcare Co. Inc. tanked more than 18% late Tuesday after the company missed third-quarter earnings and revenue expectations. Acadia said it earned $45.6 million, or 52 cents a share, in the quarter, versus a net loss of $117.8 million, or $1.36 a share, for the third quarter of 2016. Adjusted for one-time items, the company reported earnings of 58 cents a share. Revenue fell 2.4% to $716.7 million, compared with $734.7 million for the third quarter of 2016. Analysts polled by FactSet had expected adjusted earnings of 65 cents a share on sales of $726 million.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Tenet announces early exit of CEO as it continues to seek permanent successor
Tenet Healthcare Corp. on Monday said Trevor Fetter has stepped down as chief executive and resigned from the board effective immediately. The company had said in August that Fetter would resign by March 15 or when a successor had been found. Instead, the board named Executive Chairman Ronald Rittenmeyer as CEO while the company continues to seek a permanent replacement. It is not clear what precipitated Fetter's exit. Shares of Tenet were flat in the extended session after closing at $14.69. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
UK Stocks-Factors to watch on Oct 23
Oct 23 (Reuters) - Britain's FTSE 100 index is
expected to open 2 points higher at 7,525.5 on Monday, according
to financial spreadbetters.
* GSK: GlaxoSmithKline's gene therapy for the
so-called "bubble boy" disease was approved by Britain's
healthcare cost watchdog NICE, despite a price tag of almost
600,000 euros ($700,000).
* GSK: The U.S. Food and Drug Administration approved
GlaxoSmithKline's Shingrix shingles vaccine for use in
adults aged 50 and over, a move wide
Heartland Payment SystemsHPY
Hecla Mining CompanyHL
Hecla Mining CompanyHL^B
Helix Energy Solutions GroupHLX
Helmerich & PayneHP
Hercules Technology Growth CapitalHTGC